The fusion protein of IFN-α and apolipoprotein A-I crosses the blood-brain barrier by a saturable transport mechanism

Journal of Immunology

Volumn 188, Issue 8, 2012, Pages 3988-3992

  Fioravanti, Jessica ^a   Medina Echeverz, José ^a   Ardaiz, Nuria ^a   Gomar, Celia ^a   Parra Guillén, Zinnia P ^b   Prieto, Jesús ^a,c   Berraondo, Pedro ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; STAT1 PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; CELL NUCLEUS; CONTROLLED STUDY; DIFFUSION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG PENETRATION; FEMALE; GENE INDUCTION; HYDRODYNAMICS; IMMOBILIZATION; MEMBRANE TRANSPORT; MOUSE; NERVE CELL INHIBITION; NONHUMAN; PLASMID; PRIORITY JOURNAL; TRANSGENE;

ANIMALS; APOLIPOPROTEIN A-I; BLOOD-BRAIN BARRIER; DEPRESSION; FEMALE; HALF-LIFE; HINDLIMB SUSPENSION; HUMANS; INJECTIONS, INTRAVENOUS; INTERFERON-ALPHA; LIPOPROTEINS, HDL; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS;

EID: 84860338314     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101598     Document Type: Article

References (30)

1. Isaacs, A., and J. Lindenmann. 1957. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147: 258-267.
2. Kalie, E., D. A. Jaitin, R. Abramovich, and G. Schreiber. 2007. An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. J. Biol. Chem. 282: 11602-11611. (Pubitemid 47100799)
3. Le Bon, A., N. Etchart, C. Rossmann, M. Ashton, S. Hou, D. Gewert, P. Borrow, and D. F. Tough. 2003. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4: 1009-1015. (Pubitemid 37265922)
4. Poynard, T., J. McHutchison, M. Manns, C. Trepo, K. Lindsay, Z. Goodman, M. H. Ling, and J. Albrecht. 2002. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122: 1303-1313. (Pubitemid 34465173)
5. Barnes, E., G. Webster, R. Jacobs, and G. Dusheiko. 1999. Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin. J. Hepatol. 31(Suppl. 1): 244-249. (Pubitemid 30002727)
6. Fiorani, C., S. Tonelli, B. Casolari, and S. Sacchi. 1999. The role of interferon-alpha in the treatment of myeloproliferative disorders. Curr. Pharm. Des. 5: 987-1013. (Pubitemid 30014007)
7. Glue, P., J. W. Fang, R. Rouzier-Panis, C. Raffanel, R. Sabo, S. K. Gupta, M. Salfi, and S. Jacobs; Hepatitis C Intervention Therapy Group. 2000. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin. Pharmacol. Ther. 68: 556-567.
8. Perry, C. M., and B. Jarvis. 2001. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs 61: 2263-2288. (Pubitemid 34081171)
9. Shechter, Y., L. Preciado-Patt, G. Schreiber, and M. Fridkin. 2001. Prolonging the half-life of human interferon-alpha 2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)7- interferon-alpha 2. Proc. Natl. Acad. Sci. USA 98: 1212-1217. (Pubitemid 32121212)
10. Osborn, B. L., H. S. Olsen, B. Nardelli, J. H. Murray, J. X. Zhou, A. Garcia, G. Moody, L. S. Zaritskaya, and C. Sung. 2002. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 303: 540-548. (Pubitemid 35231224)
11. Renault, P. F., J. H. Hoofnagle, Y. Park, K. D. Mullen, M. Peters, D. B. Jones, V. Rustgi, and E. A. Jones. 1987. Psychiatric complications of long-term interferon alfa therapy. Arch. Intern. Med. 147: 1577-1580. (Pubitemid 17138838)
12. Dieperink, E., M. Willenbring, and S. B. Ho. 2000. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am. J. Psychiatry 157: 867-876. (Pubitemid 30412335)
13. Dantzer, R., J. C. O'Connor, G. G. Freund, R. W. Johnson, and K. W. Kelley. 2008. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9: 46-56. (Pubitemid 350295688)
14. Greig, N. H., W. R. Fredericks, H. W. Holloway, T. T. Soncrant, and S. I. Rapoport. 1988. Delivery of human interferon-alpha to brain by transient osmotic blood-brain barrier modification in the rat. J. Pharmacol. Exp. Ther. 245: 581-586.
15. Greischel, A., P. Tanswell, U. Busch, and K. Schumacher. 1988. Pharmacokinetics and biodisposition of recombinant human interferon-alpha 2C in rat and marmoset. Arzneimittelforschung 38: 1539-1543.
16. Smith, R. A., F. Norris, D. Palmer, L. Bernhardt, and R. J. Wills. 1985. Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clin. Pharmacol. Ther. 37: 85-88. (Pubitemid 16225171)
17. Rothwell, N. J., and S. J. Hopkins. 1995. Cytokines and the nervous system II: Actions and mechanisms of action. Trends Neurosci. 18: 130-136.
18. Corssmit, E. P., R. Heijligenberg, E. Endert, M. T. Ackermans, H. P. Sauerwein, and J. A. Romijn. 1996. Endocrine and metabolic effects of interferon-alpha in humans. J. Clin. Endocrinol. Metab. 81: 3265-3269. (Pubitemid 26296200)
19. Capuron, L., G. Neurauter, D. L. Musselman, D. H. Lawson, C. B. Nemeroff, D. Fuchs, and A. H. Miller. 2003. Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol. Psychiatry 54: 906-914.
20. Kratzer, I., K. Wernig, U. Panzenboeck, E. Bernhart, H. Reicher, R. Wronski, M. Windisch, A. Hammer, E. Malle, A. Zimmer, and W. Sattler. 2007. Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. J. Control. Release 117: 301-311. (Pubitemid 46216580)
21. Kreuter, J., T. Hekmatara, S. Dreis, T. Vogel, S. Gelperina, and K. Langer. 2007. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J. Control. Release 118: 54-58. (Pubitemid 46283106)
22. Danik, M., D. Champagne, C. Petit-Turcotte, U. Beffert, and J. Poirier. 1999. Brain lipoprotein metabolism and its relation to neurodegenerative disease. Crit. Rev. Neurobiol. 13: 357-407.
23. Balazs, Z., U. Panzenboeck, A. Hammer, A. Sovic, O. Quehenberger, E. Malle, and W. Sattler. 2004. Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model. J. Neurochem. 89: 939-950. (Pubitemid 38684741)
24. Liu, F., Y. Song, and D. Liu. 1999. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6: 1258-1266. (Pubitemid 29359019)
25. Fioravanti, J., I. González, J. Medina-Echeverz, E. Larrea, N. Ardaiz, G. González-Aseguinolaza, J. Prieto, and P. Berraondo. 2011. Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties. Hepatology 53: 1864-1873.
26. Steru, L., R. Chermat, B. Thierry, and P. Simon. 1985. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl.) 85: 367-370. (Pubitemid 15123115)
27. Orsal, A. S., S. M. Blois, D. Bermpohl, M. Schaefer, and N. Coquery. 2008. Administration of interferon-alpha in mice provokes peripheral and central modulation of immune cells, accompanied by behavioral effects. Neuropsychobiology 58: 211-222.
28. Greig, N. H., T. T. Soncrant, K. M. Wozniak, and S. I. Rapoport. 1988. Plasma and tissue pharmacokinetics of human interferon-alpha in the rat after its intravenous administration. J. Pharmacol. Exp. Ther. 245: 574-580.
29. Wang, J., I. L. Campbell, and H. Zhang. 2008. Systemic interferon-alpha regulates interferon-stimulated genes in the central nervous system. Mol. Psychiatry 13: 293-301. (Pubitemid 351272648)
30. Karasinska, J. M., F. Rinninger, D. Lütjohann, P. Ruddle, S. Franciosi, J. K. Kruit, R. R. Singaraja, V. Hirsch-Reinshagen, J. Fan, L. R. Brunham, et al. 2009. Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function. J. Neurosci. 29: 3579-3589.